{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:04:56Z","timestamp":1784189096849,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01030-5","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:10:14Z","timestamp":1777961414000},"page":"819-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE"],"prefix":"10.1007","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct03720470","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04345367","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1822","authenticated-orcid":false,"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina B.","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Gregoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Koulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"2","key":"1030_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017. Br J Dermatol. 2021;184(2):304\u201330.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1030_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10\u201322.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"1030_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/derm.2022.29015.jsi","volume":"34","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Mohawk JA, Cirulli J, Nograles K, Punzalan JC, Kelly KM, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermatitis. 2023;34(2):135\u201344.","journal-title":"Dermatitis"},{"issue":"3","key":"1030_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1030_CR5","first-page":"22","volume":"16","author":"AM Snyder","year":"2023","unstructured":"Snyder AM, Taliercio VL, Brandenberger AU, Rich BE, Webber LB, Beshay AP, et al. Atopic dermatitis: a qualitative study on the burdens of living with itchiness. J Clin Aesthet Dermatol. 2023;16(7):22\u20135.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"7","key":"1030_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00403-024-03130-w","volume":"316","author":"A Wollenberg","year":"2024","unstructured":"Wollenberg A, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Patient-reported burden in adults with atopic dermatitis: an international qualitative study. Arch Dermatol Res. 2024;316(7):380.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1030_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","volume":"151","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155\u201362.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1030_CR8","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/jdv.19813","volume":"38","author":"G Biazus Soares","year":"2024","unstructured":"Biazus Soares G, Mahmoud O, Yosipovitch G, Mochizuki H. The mind-skin connection: a narrative review exploring the link between inflammatory skin diseases and psychological stress. J Eur Acad Dermatol Venereol. 2024;38(5):821\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1030_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.227","volume":"3","author":"B Halioua","year":"2023","unstructured":"Halioua B, Taieb J, Seneschal J, Corgibet F, Misery L, Marqui\u00e9 A, et al. Prevalence of excessive daytime sleepiness among patients with atopic dermatitis. Skin Health Dis. 2023;3(4):e227.","journal-title":"Skin Health Dis."},{"issue":"9","key":"1030_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/1346-8138.15939","volume":"48","author":"AL Bosma","year":"2021","unstructured":"Bosma AL, Ouwerkerk W, G\u00fcnal M, Hyseni AM, Arents BWM, Gerbens LAA, et al. Work ability and quality of working life in atopic dermatitis patients treated with dupilumab. J Dermatol. 2021;48(9):1305\u201314.","journal-title":"J Dermatol"},{"issue":"Suppl. 7","key":"1030_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.18168","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Misery L, von Kobyletzki L, Armario-Hita JC, Mealing S, Redding M. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. J Eur Acad Dermatol Venereol. 2022;36(Suppl. 7):3\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1030_CR12","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13555-023-00965-5","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Delevry D, Yang M, Chuang CC, Wang Z, B\u00e9go-Le-Bagousse G, et al. Long-term effectiveness of dupilumab in patients with atopic dermatitis: results up to 3 years from the RELIEVE-AD Study. Dermatol Ther (Heidelb). 2023;13(9):2107\u201320.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"1030_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s13555-023-00897-0","volume":"13","author":"C Paul","year":"2023","unstructured":"Paul C, Griffiths CEM, Costanzo A, Herranz P, Grond S, Mert C, et al. Factors predicting quality of life impairment in adult patients with atopic dermatitis: results from a patient survey and machine learning analysis. Dermatol Ther (Heidelb). 2023;13(4):981\u201395.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"4","key":"1030_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.382","volume":"4","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Thyssen JP, Lazariciu I, Myers DE, G\u00fcler E, Chovatiya R. Abrocitinib may improve itch and quality of life in patients with itch-dominant atopic dermatitis. Skin Health Dis. 2024;4(4):e382.","journal-title":"Skin Health Dis."},{"issue":"8","key":"1030_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/09546634.2019.1623860","volume":"31","author":"Y Okubo","year":"2020","unstructured":"Okubo Y, Ho KA, Fifer S, Fujita H, Oki Y, Taguchi Y. Patient and physician preferences for atopic dermatitis injection treatments in Japan. J Dermatolog Treat. 2020;31(8):821\u201330.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1030_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1080\/09546634.2020.1832185","volume":"33","author":"M Boeri","year":"2022","unstructured":"Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, Di Bonaventura M. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatolog Treat. 2022;33(3):1449\u201358.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1030_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019;81(4):943\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1030_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2340\/00015555-2480","volume":"97","author":"LB von Kobyletzki","year":"2017","unstructured":"von Kobyletzki LB, Thomas KS, Schmitt J, Chalmers JR, Deckert S, Aoki V, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol. 2017;97(1):86\u201390.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1030_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jdv.18170","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Bhatia N, Gooderham MJ, Silverberg JI, Thyssen JP, Biswas P, et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022;36(8):1308\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1030_CR20","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.","journal-title":"Acta Derm Venereol"},{"key":"1030_CR21","unstructured":"Regeneron Pharmaceuticals Inc. Dupixent (dupilumab). Summary of product characteristics. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent. Accessed 13 Feb 2024."},{"key":"1030_CR22","unstructured":"Dupixent\u00ae (dupilumab) injection, for subcutaneous use. Prescribing information. Tarrytown (NY): Regeneron Pharmaceuticals Inc.; 2019."},{"key":"1030_CR23","unstructured":"Cibinqo\u00ae (abrocitinib) tablets, for oral use. Prescribing information. New York (NY): Pfizer Inc.; 2022."},{"key":"1030_CR24","unstructured":"Japan's MHLW approves Pfizer's Cibinqo\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis [press release]. New York (NY): Pfizer Inc.; 30 Sep 2021."},{"key":"1030_CR25","unstructured":"Cibinqo\u00ae (abrocitinib). Product monograph including patient medication information. Quebec (QC): Pfizer Canada Inc.; 2022."},{"key":"1030_CR26","unstructured":"Pfizer Inc. CIBINQO. Summary of product characteristics. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf. Accessed 20 Nov 2024."},{"issue":"10348","key":"1030_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"12","key":"1030_CR28","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI. Abrocitinib versus placebo and dupilumab for atopic dermatitis. N Eng J Med. 2021;384(12):1101\u201312.","journal-title":"N Eng J Med"},{"issue":"3","key":"1030_CR29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jdv.17813","volume":"36","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Yosipovitch G, Paul C, Kwatra SG, Chu CY, DiBonaventura M, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(3):434\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1030_CR30","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"1030_CR31","doi-asserted-by":"publisher","first-page":"2290120","DOI":"10.1155\/2021\/2290120","volume":"2021","author":"G D'Arrigo","year":"2021","unstructured":"D\u2019Arrigo G, Leonardis D, Abd ElHafeez S, Fusaro M, Tripepi G, Roumeliotis S. Methods to analyse time-to-event data: the Kaplan-Meier survival curve. Oxid Med Cell Longev. 2021;2021:2290120.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"1030_CR32","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Silverberg JI, Thyssen JP, Viguier M, Tha\u00e7i D, de Bruin-Weller M, et al. Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase 3 JADE COMPARE Trial. Am J Clin Dermatol. 2023;24(4):609\u201321.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1030_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40257-022-00738-4","volume":"24","author":"S St\u00e4nder","year":"2023","unstructured":"St\u00e4nder S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: subgroup analysis of the randomized phase III JADE COMPARE Trial. Am J Clin Dermatol. 2023;24(1):97\u2013107.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1030_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1030_CR35","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s13555-023-01038-3","volume":"13","author":"H Penton","year":"2023","unstructured":"Penton H, Jayade S, Selveindran S, Heisen M, Piketty C, Ulianov L, et al. Assessing response in atopic dermatitis: a systematic review of the psychometric performance of measures used in HTAs and clinical trials. Dermatol Ther (Heidelb). 2023;13(11):2549\u201371.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"13","key":"1030_CR36","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2340\/00015555-3332","volume":"99","author":"C Riepe","year":"2019","unstructured":"Riepe C, Osada N, Reich A, Augustin M, Zeidler C, St\u00e4nder S. Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity. Acta Derm Venereol. 2019;99(13):1288\u201390.","journal-title":"Acta Derm Venereol"},{"key":"1030_CR37","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"12","key":"1030_CR38","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1030_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"6","key":"1030_CR40","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s11136-021-02770-z","volume":"30","author":"JS Barbieri","year":"2021","unstructured":"Barbieri JS, Chiesa Fuxench ZC, Shin DB, Takeshita J. Frequency and influence of \u201cnot relevant\u201d responses on the Dermatology Life Quality Index among adults with atopic dermatitis. Qual Life Res. 2021;30(6):1705\u201313.","journal-title":"Qual Life Res"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01030-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01030-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:21:54Z","timestamp":1784186514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01030-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01030-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gil Yosipovitch is an Editorial Board member of American Journal of Clinical Dermatology. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Gil Yosipovitch has been a consultant and an advisor for Pfizer Inc., AbbVie, Almirall, Amgen, Arcutis, Celldex, Eli Lilly, Escient Health, Galderma, GSK, Kiniksa, LEO Pharma, Merck, Novartis, Pierre Fabre, Sanofi-Regeneron, and Vifor, and a principal investigator for and grant recipient of Pfizer Inc., Eli Lilly, Escient Health, Galderma, Kiniksa, LEO Pharma, Novartis, Pierre Fabre, and Sanofi-Regeneron. Melinda J. Gooderham has received grants, personal fees, honoraria, and\/or nonfinancial support from Pfizer Inc., AbbVie, Amgen, Akros\u00a0Pharma, Arcutis, AnaptysBio, Aristea, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, MoonLake, Meiji, Nektar, Novartis, Roche, Sanofi-Genzyme, Regeneron Pharmaceuticals, Sun Pharma, UCB, Ventyx, and Bausch Health. Sarina B. Elmariah has been a consultant and an advisor for Pfizer Inc., Celldex, Galderma, Regeneron Pharmaceuticals, and Sanofi. Gianluca Bonfanti is a stakeholder of Engineering Ingegneria Informatica, a paid consultant contracted by Health Services Consulting Corporation in connection with this study. Health Services Consulting Corporation was a paid contractor to Pfizer Inc. in connection with the formal data analysis for this study. Roger A. Edwards is an employee of Health Services Consulting Corporation and received consultancy fees from Pfizer in connection with this study. Stamatios Gregoriou is or recently was a speaker and\/or advisor for AbbVie, Eli Lilly & Co, LEO Pharma, Pfizer, Sanofi-Genzyme, and Janssen and has received research funding from AbbVie and Novartis. Pinaki Biswas, Daniela E. Myers, Justine Alderfer, Erman G\u00fcler, and Christopher Koulias are employees and shareholders of Pfizer Inc.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study documents and procedures were approved by the appropriate institutional review boards\/ethics committees at each study site. The studies were conducted in compliance with the ethical principles from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice Guidelines. All local regulatory requirements were followed.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\n                      \n                      for more information.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following software application was used in the analysis for this manuscript: SAS 9.4.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GB, RAE, PB, EG, and CK contributed to the study conceptualization and design. GB, RAE, and PB conducted the statistical analysis. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}